For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 37,617 | 63,520* | 32,167 | 27,720 |
| General and administrative | 8,494 | 6,105* | 6,149 | 5,903 |
| Total operating expenses | 46,111 | 69,625 | 38,316 | 33,623 |
| Operating loss | -46,111 | -69,625* | -38,316 | -33,623 |
| Interest and investment income | 2,791 | 2,883* | 3,338 | 2,224 |
| Net loss | -43,320 | -66,742* | -34,978 | -31,399 |
| Unrealized loss (gain) on marketable securities | -284 | -112 | 226 | -1 |
| Total other comprehensive loss (gain) | -284 | -112* | 226 | -1 |
| Total comprehensive loss | -43,604 | -66,855 | -34,752 | -31,400 |
| Basic EPS | -0.96 | -1.738 | -0.83 | -0.9 |
| Diluted EPS | -0.96 | -1.738 | -0.83 | -0.9 |
| Basic Average Shares | 45,067,658 | 38,468,781 | 41,912,905 | 35,006,114 |
| Diluted Average Shares | 45,067,658 | 38,468,781 | 41,912,905 | 35,006,114 |
ArriVent BioPharma, Inc. (AVBP)
ArriVent BioPharma, Inc. (AVBP)